Alpha Adhesives & Sealants Ltd

alpha-adhesives.co.uk

Established in 1987 Alpha has become a worldwide supplier of quality Adhesives, Sealants & coatings that are manufactured at its UK base in Stourport on Severn, Worcestershire. In 2004 Alpha acquired the Industrial Adhesives Division of DUNLOP who's origins date back to the early 1900's and are synonymous with brand names such as thixofix. Alpha have the commitment and ability to develop and manufacture products for particular specialist applications and prides itself with offering customers a working partnership in order to achieve the best possible results together.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

news image

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

news image

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More

Business Insights

SCA PHARMA NAMES LOUIS PACE AS CHIEF FINANCIAL OFFICER AND CHIEF INFORMATION OFFICER

SCA Pharma | July 15, 2022

news image

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L leadership roles. Most recently, Mr. Pace served as Chief Financial Officer at Orchid O...

Read More

PHARMACY MARKET, PHARMA TECH

MERCK & XTALPI COLLABORATION OPTIMIZES DRUG FORMULATIONS WITH AI-POWERED TECHNIQUES

prnewswire | April 18, 2023

news image

Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development. Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. In contrast, molecular dynamics simulations...

Read More
news image

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More
news image

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More
news image

Business Insights

SCA PHARMA NAMES LOUIS PACE AS CHIEF FINANCIAL OFFICER AND CHIEF INFORMATION OFFICER

SCA Pharma | July 15, 2022

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L leadership roles. Most recently, Mr. Pace served as Chief Financial Officer at Orchid O...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MERCK & XTALPI COLLABORATION OPTIMIZES DRUG FORMULATIONS WITH AI-POWERED TECHNIQUES

prnewswire | April 18, 2023

Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development. Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. In contrast, molecular dynamics simulations...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us